Astellas Gene Therapies in the news
Developing genetic medicines
Tamtam found 15 recent articles about Astellas Gene Therapies.
- A Gene-Therapy Pioneer Just Filed For Chapter 11 Bankruptcy—Now Eli Lilly Wants Its Tech
Gene-therapy pioneer Sangamo Therapeutics filed for bankruptcy, with Eli Lilly and Astellas bidding for its assets.
- UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy
Sangamo Therapeutics is filing for bankruptcy and selling its assets, with Eli Lilly acquiring several platforms and programs, and Astellas securing a pivotal-stage gene therapy for Fabry disease.
- Report details damage to sensory nerve cells with Pompe gene therapy in case
A patient in a clinical trial for Astellas Gene Therapies' AT845 developed sensory nerve damage post-treatment for Pompe disease, prompting recommendations for close neurological monitoring in gene therapy recipients.
- Astellas retries XLMTM gene therapy after deaths
Astellas is restarting trials for its XLMTM gene therapy, while Intellia's CRISPR therapy for hereditary angioedema showed promising results, and other companies made significant acquisitions and trial announcements.
- Astellas Licenses Dyno Therapeutics’ AI-Designed AAV Capsid, Advancing Gene Delivery for Muscle Disorders
Astellas licensed an AI-designed AAV capsid from Dyno Therapeutics for muscle disorder gene delivery, including a $15 million upfront payment.
- Astellas unearths Dyno muscle disorder AAV capsid with $15M option agreement
Astellas licensed a Dyno Therapeutics gene therapy vehicle, an adeno-associated virus capsid, for skeletal muscle delivery, involving a $15 million fee to Dyno.
- Astellas Takes Aim at XLMTM Again, Now with MyoAAV Capsid-Based Gene Therapy
Astellas is advancing a new, safer MyoAAV gene therapy for X-linked Myotubular Myopathy, ASP2957, entering Phase I/II trials, while also progressing other genetic medicine programs and capsid development.
- Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More
Astellas is expanding its pipeline in cancer, gene therapy for neuromuscular disorders, and women's health, combining internal development with strategic acquisitions and partnerships.
- Astellas Gene Therapies to Close Biomanufacturing Facility, Affecting About 100 Employees
Astellas Gene Therapies is closing its San Francisco biomanufacturing facility, affecting about 100 employees, to consolidate operations in North Carolina.
- In analysis of gene therapy deaths, Astellas points to underlying liver issues
Astellas attributes four deaths in its AT132 gene therapy trial to underlying liver issues in patients with X-linked myotubular myopathy.
- Staying the Course: New CEO, Same Focus for Astellas Gene Therapies
Astellas Pharma's new CEO will maintain the company's focus on gene therapy development, despite ongoing clinical hold challenges for some lead candidates.
- Astellas, despite recent setbacks, opens $100M gene therapy plant
Astellas opened a $100 million gene therapy plant in North Carolina despite recent setbacks and patient deaths in its lead gene therapy program.
- Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina
Astellas Gene Therapies opened a $100 million, 135,000 square-foot gene therapy manufacturing facility in Sanford, N.C., creating over 200 jobs to support clinical and commercial production of its AAV gene therapies.
- Fourth trial volunteer dies in Astellas gene therapy study
A fourth child died in Astellas' gene therapy trial for X-linked myotubular myopathy due to abnormal liver function, leading to the study's re-suspension.
- Audentes Therapeutics Expands Mission, Becomes Astellas Gene Therapies
Audentes Therapeutics has rebranded as Astellas Gene Therapies, expanding its mission within Astellas to develop genetic medicines.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Astellas Gene Therapies?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies